Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Bristol Myers Squibb announces positive Phase 3 results for Mezigdomide in MM

Bristol Myers Squibb reached a major milestone in its next-generation protein degradation program on Monday, reporting that its oral CELMoD agent, mezigdomide, significantly extended the time patients lived without their cancer progressing in a pivotal Phase 3 study.

Leia mais: Bristol Myers Squibb announces positive Phase 3 results for Mezigdomide in MM
Grafa
Health

Pfizer's Tilrekimig hits primary endpoint in atopic dermatitis Phase 2 trial

Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.

Leia mais: Pfizer's Tilrekimig hits primary endpoint in atopic dermatitis Phase 2 trial
Grafa
Technology

Korn Ferry fee revenue surges 7% as digital and consulting demand diversifies

Korn Ferry (NYSE:KFY) reported a strong third quarter for fiscal 2026, with fee revenue reaching $717.4 million as the global consulting firm successfully leveraged high-growth digital services and long-term contracts to offset broader economic shifts.

Leia mais: Korn Ferry fee revenue surges 7% as digital and consulting demand diversifies